Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

AvevoRx Launches Nationwide Specialty Infusion Pharmacy Service for Patients Facing Complex and Chronic Health Disorders


“With AvevoRx, we are investing in a future that prioritizes a patient’s most basic, fundamental needs – a welcoming human voice on the other end of the phone, a single point of contact for care navigation – and making that a part of their customized care plan.”

A group of seasoned, specialty pharmacy and home infusion executives, with a combined 130 years of industry experience, have announced the formation of AvevoRx, a national, independent provider of specialty infusion pharmacy services. The venture brings bespoke services and clinical care to patients facing various complex and chronic disorders who receive a range of intravenous medication therapies. AvevoRx is based out of Greensboro, North Carolina.

The AvevoRx co-founders are industry veterans of private and public companies who serve as the management team and bring deep experience in building and scaling specialty infusion therapy platforms. The company entered the market by acquiring Mid Valley Health Services, a long-established infusion company based in Modesto, Calif. Concurrent with the Mid Valley acquisition, AvevoRx opened a new pharmacy distribution center in Greensboro, N.C. The company expects to execute at least one additional acquisition before the year’s end.

“In building AvevoRx, we are investing in a future that prioritizes a patient’s most basic, fundamental needs – a welcoming human voice on the other end of the phone, a single point of contact for care navigation – and making that a part of their customized care plan,” said Robin Johnson, Co-founder and Chief Financial Officer of AvevoRx.

“The addition of Mid Valley Health Services to the AvevoRx family reinforces the core tenants of our specialized, personal care model by bringing in an amazing group of accomplished professionals in the California market,” said Lauren Pumphrey, Co-founder, and head of western-U.S. sales. “With a track record of more than 25 years of regional excellence, AvevoRx has the right foundation upon which to build.”

“Specialty infusion pharmacies are not always special, so we have set out to change that,” said Courtney Remley, Co-Founder, and head of eastern-U.S. sales. “AvevoRx is committed to remaining an independent provider that earns its reputation for scrappy, hard work and going the extra mile for patients.”

The founding management team for AvevoRx includes:


  • Eric Hill, Co-Founder, brings more than 30 years of specialty infusion experience to AvevoRx. Eric is the former Chief Operating Officer of Diplomat Specialty Infusion Group, which he came to via the acquisition of BioRx, the company he co-founded in 2004. The company would enjoy organic and acquisition-driven growth to become a leading specialty infusion platform with more than 800 employees, $1 billion in revenue, and approximately $100mm in EBITDA. Prior, Eric served in various Vice President roles for Coram Healthcare over a 10-year period, where as VP of Blood Products he grew the business from $30mm to $175mm in just a few years. Eric earned his Bachelor of Arts degree in Psychology from Wake Forest University in Winston-Salem, North Carolina. He splits his time between N.C and Florida.
  • Phil Rielly, Co-Founder, served as President of Diplomat Specialty Infusion Group until August 2020. He joined Diplomat Specialty Infusion Group in 2014 with the acquisition of BioRx, LLC, the company he co-founded with Eric Hill in 2004. Prior, Phil co-founded CliniCare, a respiratory equipment provider, and PRO2, a business serving the respiratory therapy market. Phil’s healthcare career began with Apria in 1992. He gained specialty pharmaceutical experience with Alpha Therapeutics and Coram, where he served as area market director for the blood products division. Phil earned his Bachelor of Arts in communications and marketing from Spring Hill College in Alabama.
  • Robin Johnson, CPA, Co-Founder, and Chief Financial Officer, brings 30+ years of professional, public, and private accounting experience to AvevoRx, with expertise in various healthcare and software verticals. She served as Chief Financial Officer for Diplomat Specialty Infusion Group through June of 2020 with oversight of eleven legal entities, eight of which were acquired during her tenure, and contributed greatly to Diplomat’s position as a leading national specialty infusion platform. Prior, Robin served as Vice President and Chief Accounting Officer for VITAS Healthcare Corporation, one of the nation’s oldest and largest providers of end-of-life care. Robin became a certified public accountant through the Kentucky State Board of Accountancy and earned her MBA from Morehead State University, Ky.
  • Lauren Pumphrey, Co-Founder, and head of western-U.S. sales, brings 9 years of experience in the specialty infusion industry to AvevoRx. Most recently, she served as regional business director for mid-Atlantic and southeast markets at OptumRx (previously Diplomat Specialty Infusion Group). Prior, she served as the west coast regional sales director, overseeing $127 mm in revenue. Concurrent with her management responsibilities, Lauren personally built and grew the leading U.S. sales territory, delivering more than $33 mm in annual revenue in just over 3 years. Lauren’s strengths are in establishing and scaling up businesses in new and untapped markets, including several in rural Indiana, Missouri, and Massachusetts. She ended 2020 as the top growth performer in the U.S., along with building a full team for the western region. She was an active participant in new therapy launches as a member of the advisory board, which serves as the committee for strategy development for new products. Lauren graduated with a degree from Ball State University in business with a minor in international studies.
  • Courtney Remley, Co-Founder, and head of eastern-U.S. sales, brings to AvevoRx more than 17 years in the healthcare and specialty infusion services industry. Most recently, she served as a senior national account manager for the specialty infusion division at OptumRx (previously Diplomat Specialty Infusion Group). Over her 11-year tenure at OptumRx and predecessor companies, she grew her region by 1,233%, representing regional revenue of over $12 million annually. Her focus centered on the development, contracting, and implementation of a large national contract that is innovative and transformative for the industry. Before her time in specialty infusion, she served as a sales leader and manager in long-term care, acute rehabilitation, and home healthcare industries. Courtney resides in South Carolina where she serves on multiple non-profit boards and committees. Courtney is a graduate of Purdue University with a major in Audiology and Speech Sciences.

AvevoRx currently serves patients in several states and continues to grow. Visit http://www.AvevoRx.com to learn more or call 877-AvevoRx.

About AvevoRx

AvevoRx is a bespoke, independent provider of specialty infusion pharmacy services. The company focuses on the highest-quality, personalized care customized to patients facing various complex, chronic disorders. Treatments are made available via specialized pharmacy locations, field nurses, and additional support staff throughout the United States. AvevoRx also provides acute infusion therapies for patients with short-term therapeutic needs on a regional basis. Privately held, the company was founded in 2021 by a small group of industry veterans with a combined experience of more than 130 years. AvevoRx is headquartered in North Carolina. To learn more, visit http://www.AvevoRx.com or follow us on Instagram or LinkedIn.

###

Share article on social media or email:



Prevent Blindness Offers New Educational Resources for November’s Diabetes-related Eye Disease Awareness Month


Prevent Blindness offers new, comprehensive resources for November’s Diabetes-related Eye Disease Month.

“Many people with diabetes may not know about the damaging effects the disease can have on vision,” said Jeff Todd, Prevent Blindness president and CEO.

According to the 2022 National Diabetes Statistics Report from the Centers for Disease Control and Prevention, more than 11 percent of the U.S. population (approximately 37.3 million people) have diabetes. Alarmingly, 96 million people aged 18 years or older have prediabetes (38 percent of the adult US population). And, diabetes is the leading cause of new cases of blindness among adults aged 18–64 years.

Prevent Blindness, the nation’s leading nonprofit eye health and safety organization, has declared November as Diabetes-related Eye Disease Awareness Month in an effort to provide the public with a variety of helpful tools to prevent unnecessary vision loss from diabetes.

A new episode of the Prevent Blindness Focus on Eye Health Expert Series dedicated to diabetes-related eye disease and health disparities will also be available during November. Jeff Todd, president and CEO of Prevent Blindness, will interview Kristen Nwanyanwu, MD, MBA, MHS, Associate Professor of Ophthalmology and Visual Science, Yale School of Medicine. Dr. Nwanyanwu is the principal investigator at the SEEN Lab (Sight-Saving Engagement and Evaluation in New Haven).

In 2022, Prevent Blindness revamped its popular Diabetes & the Eyes Educational Toolkit, available in English and Spanish, which includes educational resources, such Power Point presentations, shareable social media graphics and a dedicated webpage. Fact sheets, including the new “Diabetes-related Eye Disease and Mental Health” fact sheet are also available. These resources are intended for healthcare professionals, community health educators, and those in a caregiving or diabetes education role.

The Diabetes & The Eyes program, supported by funding from Regeneron, also includes:

*Comprehensive Video Series- Prevent Blindness produced a new series of videos, including “Diabetes, Vision Loss, and Mental Wellness.”

*Videos funded in part by Focus on Diabetes™, an eye health initiative of the American Diabetes Association® include: “The Patient Perspective: Diabetes-related Eye Disease,” and the upcoming videos “Newly Diagnosed with Diabetes: What you need to know about your eyes” ” Patient centered care”, “Advice from a patient living with diabetes”, “Vision loss and diabetes,” and “Introduction to the Diabetes + the Eyes Educational Toolkit.”

*Patient Education Webinar- Panelists of the “Diabetes and Your Eyes: A Conversation Around Patient-Centered Care” webinar discuss how health care providers coordinate care for persons with diabetes, talk with each other, and consider patient needs. Leading doctors from throughout the United States who care for individuals with diabetes as well as person with diabetes participate in the conversation.

*Community-Level Health Education and Support- Prevent Blindness affiliates across the country continue to work with other local partner organizations to educate the public on a variety of vision and eye health issues related to diabetes, and offer support resources.

“Many people with diabetes may not know about the damaging effects the disease can have on vision,” said Jeff Todd, Prevent Blindness president and CEO. “We thank our partners for helping us educate the public on the steps that can be taken today in order to help save sight from diabetes-related eye disease.”

For more information on the “Diabetes & the Eyes” program, please visit https://www.preventblindness.org/diabetes-and-eyes-educational-toolkit. For general diabetes information, visit http://preventblindness.org/diabetes. For a free listing of organizations and services that provide financial assistance for vision care in English or Spanish, please visit https://preventblindness.org/vision-care-financial-assistance-information/.

About Prevent Blindness

Founded in 1908, Prevent Blindness is the nation’s leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy, certified vision screening and training, community and patient service programs and research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at PreventBlindness.org, and follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

###

Share article on social media or email:

The Max Foundation Announces Multi-Stakeholder Collaboration to Improve Outcomes for People Living with Advanced Breast Cancer in Low-Resource Countries


News Image

“We are humbled by the opportunity to address the leading cause of cancer deaths among women globally and grateful to our founding partners who share our belief that geography should not be destiny for people living with advanced breast cancer,” said Pat Garcia-Gonzalez, CEO of The Max Foundation.

The Max Foundation Announces Multi-Stakeholder Collaboration to Improve Outcomes for People Living with Advanced Breast Cancer in Low-Resource Countries


  • Humanitarian Partnership for Access to Cancer Treatment (PACT) to launch in 5 countries in 2023 providing access to treatment and support for HR+/HER2- advanced breast cancer
  • The Max Foundation, the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid and Novartis AG are joining and committing resources to a unique collaboration
  • Breast cancer is the leading cause of death for women worldwide and patients in low-resource settings face delayed diagnosis and poor access to treatment and care

The Max Foundation (Max), a global non-profit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to cancer patients, today announced a multi-stakeholder collaboration to improve outcomes for people living with HR+/HER2- advanced breast care in low- and middle-income countries (LMICs).

The Humanitarian Partnership for Access to Cancer Treatments (PACT) is a collaboration among professional, nonprofit and commercial organizations that share the commitment of The Max Foundation to increase global access to treatment, care, and support for people living with cancer. Next year, The Max Foundation will expand this innovative partnership model to include treatment for advanced breast cancer. Founding partners of the Humanitarian PACT for Advanced Breast Cancer include the ABC Global Alliance, the American Society of Clinical Pathology, Cepheid and Novartis AG. Novartis is a member of the Humanitarian PACT through CancerPath to Care, an access partnership between Max and Novartis that provides innovative medicines free of charge to people living with certain cancers in more than 70 lower-income countries.

“While there is great worldwide awareness of breast cancer today, the urgent needs of people living with advanced breast cancer in low-resource countries have been overlooked. Expanding our focus to include advanced breast cancer is in line with our commitment to helping those whom no one else is helping,” said Pat Garcia-Gonzalez, CEO of The Max Foundation. “We are humbled by the opportunity to address the leading cause of cancer deaths among women globally and grateful to our founding partners who share our belief that geography should not be destiny for people living with advanced breast cancer in low-resource countries.”

Partners in the Humanitarian PACT for Advanced Breast Cancer have agreed to invest resources and/or their unique organizational knowledge and capabilities to support the expansion of the Organization’s Max Access Solutions (MAS) to provide access to treatment for HR positive/HER2 negative advanced breast cancer. MAS is a proven treatment access model that harnesses the power of partnerships and prioritizes individual patients’ needs to improve outcomes for cancer in low-resource healthcare settings. More than 100,000 people have received access to treatment through MAS, which now operates in over 70 low-resource countries.

Preparations underway for launch of the new initiative include engagement of additional partners, expansion of in-country teams, growth of the physician network to treat patients and introduction of health systems strengthening programs such as diagnostics and supportive care. Patients enrolled in the program will receive the medication and support free-of-charge. In collaboration with its partners, Max will initially provide access to breast cancer treatments to patients in five countries next year, expanding to 28 countries by 2025. With the addition of breast cancer, starting in 2023, The Max Foundation will provide access to cancer treatments for 12 different diseases in over 70 low-resource countries.

Breast Cancer in LMICS Breast cancer is the most common cancer in women. Approximately 2.2 million cases occur each year worldwide with about 700,00 deaths annually. An estimated 45% of new cases diagnosed each year, and more than 55% of breast cancer-related deaths occur in LMICs. Managing breast cancer in low-resource countries poses unique challenges including access to screening and timely diagnosis, stage at presentation, adequacy of management, and availability of therapeutic interventions. For example, routine pathology, diagnostic exams, and standard breast cancer medicines are often unavailable. Breast cancer is usually diagnosed at late stages, and due to limited resources, patients with breast cancer may receive inadequate treatment including supportive and palliative care.

About The Max Foundation

The Max Foundation (Max) is a global health nonprofit organization dedicated to accelerating health equity. For 25 years, Max has pioneered practical, scalable, high-quality solutions to bring lifesaving treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope. Learn more at http://www.themaxfoundation.org

Quotes from our Partners about expansion of Humanitarian PACT to Advance Breast Cancer

ABC Global Alliance

“The ABC Global Alliance defined the most urgent and actionable goals in the field of metastatic/advanced breast cancer, with and for the patients, that comprise the ABC Global Charter. Ensuring that patients with ABC have access to treatment regardless of their ability to pay, is one of such goals. We are honored and proud to be part of this initiative that will greatly contribute to this goal.”

Fatima Cardoso, Director of the Breast Unit, Champalimaud Clinical Centre, Lisbon, Portugal, and President of the ABC Global Alliance

American Society of Clinical Pathology (ASCP)

“An accurate diagnostic test is at the core of every successfully treated cancer patient. Ensuring that every patient receives an accurate, rapid diagnosis of their cancer is at the heart of ASCP’s patient-centric global health mission. We are thrilled for the Max Foundation to tackle one of the major killers of women, breast cancer, and are delighted to support the diagnostic quality assurance with Max for this impactful effort.”

ASCP CEO Dr. Blair Holladay, PhD, MASCP, SCT(ASCP)CM

Cepheid

“Breast cancer diagnostics are a major focus area of the oncology efforts at Cepheid, so we are thrilled at this opportunity to extend our successful ten-year partnership with the Max Foundation to help patients with advanced breast cancer get the diagnosis and treatment that they need.”

Scott Campbell, SVP and GM for Oncology at Cepheid.

Novartis AG

“Novartis is committed to helping ensure that our medicines are accessible to as many patients as possible, irrespective of the country in which they live. Our two-decade-long partnership with The Max Foundation which has helped tens of thousands of patients access innovative oncology medicines reflects this commitment. We are excited to expand our collaboration with Max and all the partners in the Humanitarian PACT to improve outcomes for people living with advanced breast cancer in low-resource countries.”

Dr. Lutz Hegemann, President Global Health & Sustainability, Novartis AG

About the ABC Global Alliance

Established in 2016, the ABC Global Alliance originated as an initiative of the European School of Oncology and registered as a non-profit association in Portugal in 2019. It is a multi-stakeholder platform for all those interested in collaborating on common projects relating to advanced breast cancer (ABC), aiming to improve and extend the lives of women and men living with ABC worldwide and to fight for a cure. It consists of more than 200 members across 93 countries. Learn more at: http://www.abcglobalalliance.org

About American Society of Clinical Pathology

The American Society for Clinical Pathology unites more than 100,000 anatomic and clinical pathologists, medical laboratory professionals, residents, and students to accelerate the advancement of laboratory medicine to better improve patient care through knowledge, collaboration, and global community. Visit https://www.ascp.org/content/home

About Cepheid

Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company’s solutions deliver a better way for institutions of any size to perform sophisticated molecular testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, fast, and actionable test results are needed most, such as managing infectious diseases and cancer. For more information, visit http://www.cepheid.com.

About Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at https://www.novartis.com.

# # #

Media Contact: Geoff Cook

+1-973-652-7927

How Early Detection & Diagnostic Products Will Shape the Future of Healthcare, Upcoming Webinar Hosted by Xtalks


The historic utilization of currently available screening tools indicates significant barriers to the greater adoption of new diagnostic methods and products.

The clinical trial pipeline of early detection and diagnostic products is rapidly expanding. Since healthcare can often be better characterized as “sick care,” this expansion holds great promise for intersecting with patients earlier in their disease progression to improve outcomes. However, the historic utilization of currently available screening tools indicates significant barriers to the greater adoption of new diagnostic methods and products.

What impacts the diagnostic process within healthcare? How can the lessons learned from these barriers inform clinical trial design to reduce the gap from discovery to utilization and payor coverage?

In this webinar, the featured speakers will explore the barriers between healthcare and new early detection and diagnostic methods and how the strategies used to overcome such challenges can be applied to clinical research, ultimately translating to a more patient-centered trial experience and faster adoption of life-improving and lifesaving tools.

Register for this Elligo Elite Learning Series webinar for expert insights and an engaging discussion on how early detection and diagnostic products will shape the future of healthcare.

Join experts from Elligo Health Research®, Faith Holmes, MD, Medical Director, Senior Vice President of Medical Affairs; and Dawn Sauro, Executive Vice President, Research Strategy, for the live webinar on Monday, November 14, 2022, at 12pm EST (5pm GMT/UK).

For more information, or to register for this event, visit How Early Detection & Diagnostic Products will Shape the Future of Healthcare.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Fresh Tri Partners with Walmart to Add Chronic Condition Management to its Habit Building App for Walmart Associates to Improve Their Health Between Clinician Visits


“At Fresh Tri, our goal is to provide cutting-edge behavioral software that helps individuals build a long-term healthy lifestyle they love,” said Kyra Bobinet, MD, MPH, Fresh Tri’s Founder and CEO.

Fresh Tri®, a neuroscience-based digital health company, recently released an update to its healthy habit-formation software, licensed by Walmart for its 1.6 million associates since 2017. The behavior-change app uses clinical guideline-based algorithms to now support chronic condition management, personalizing each care journey to improve outcomes, continuity, and retention between clinician visits.

According to the Centers for Disease Control and Prevention, six in ten Americans live with chronic conditions, which are a major contributor to the costs of health insurance premiums and employee medical claims. Fresh Tri provides a custom behavior-change platform that matches associates with evidence-based practices that have been shown to improve chronic conditions.

The platform leverages the Iterative Mindset Method™, a unique practice-and-adapt approach, to build lasting daily health habits that align with the user’s personality, lifestyle, needs and capacity.

“At Fresh Tri, our goal is to provide cutting-edge behavioral software that helps individuals build a long-term healthy lifestyle they love,” said Kyra Bobinet, MD, MPH, Fresh Tri’s Founder and CEO. “The clinical algorithms app update creates a highly personalized experience for each person by identifying habits to practice that are clinically proven to address their specific health conditions and fostering a more connected experience between patients and clinicians. Our platform now has the ability to close behavior-change gaps between clinician visits for any patient and nearly any condition.”

Key enhancements to the Fresh Tri app include:

  • Improved onboarding to help people find the right “starting point” based on their specific behavioral history and motivation
  • New neurotyping and clinical algorithms designed to match users to the right behavior at the right time through behavioral assessments
  • Updated home screen to make practice and iteration easier and more rewarding
  • More than 1,500 new clinical evidence- and guideline-based behaviors to support condition and disease management
  • Personalization engine to provide users with constantly refreshed guidance based on engagement, progress, and milestones
  • Over 600 mindset video trainings to build daily habits and solve everyday health problems

To date, the Fresh Tri app has over 363K downloads and 200k users. A free version of the app is available to Walmart associates and their families through the App Store and Google Play. Fresh Tri is customizable for clinicians, employers and healthcare organizations seeking to support weight loss and metabolic conditions, as well as various other clinical healthy-habit changes.

About Fresh Tri

Fresh Tri is a neuroscience-based technology company with offerings leveraging mindset, practice, and iteration that invite people to test-drive healthy, evidence-based habits, removing the guesswork and feelings of failure that can often accompany lifestyle change. Fresh Tri empowers users to be unstoppable by iterating their way to better health. There is no “fail” – only practice and iteration. Fresh Tri uses a simple, positive approach based on the science of habit formation and lasting behavior change. Find out more about Walmart + Fresh Tri partnership at freshtri.com, Instagram, Facebook, and LinkedIn.

Share article on social media or email:



Process Intensification in AAV Gene Therapy, Upcoming Webinar Hosted by Xtalks


One of the major bottlenecks, addressed in this webinar, is the problem of low manufacturing yield.

Gene therapy holds the potential to dramatically change healthcare for the better. Many of these viral therapies address patient populations that have no other options for treatment. AAV is one of the leading viral vectors for gene therapy applications, with a well-characterised safety profile, and (relatively) low immunogenicity. The initial approved gene therapy products on the market, such as Luxturna (2017) and Zolgensma (2019) utilize AAV as the delivery vehicle.

However, while new AAV therapies are being constantly developed, the manufacturing capacity for viral vectors is not able to address the demand. Some estimates indicate, for example, that the entire current capacity of the viral manufacturing industry is only capable of supplying a fraction of the viral vector doses needed to address Duchenne muscular dystrophy patients, a single disease indication. Novel solutions need to be applied to bottlenecks within the manufacturing process to supply the needs of patients waiting for these therapies. One of the major bottlenecks, addressed in this webinar, is the problem of low manufacturing yield.

Historically, viral manufacturers will focus on three major categories to increase yield: cell line and vector engineering, media optimization and bioreactor design. These methods often provide substantial increases to yield. However, none of them address antiviral defences in production cells. These defences actively attack and degrade foreign genetic material used to make viruses, as well as the viral products made by the cell. As a result, viral yield on a per-cell basis can be significantly affected.

Register for this webinar to learn about process intensification and the role of antiviral defences in AAV gene therapy systems.

Join Prof. Amine Kamen, Professor, McGill University; Dr. Sarah Wootton, Associate Professor, University of Guelph; and Dr. Jean-Simon Diallo, CEO, Virica Biotech, for the live webinar on Monday, November 14, 2022, at 2:30pm EST.

For more information, or to register for this event, visit Process Intensification in AAV Gene Therapy.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

ODG by MCG’s Dave Kukielka to Join Panel at Sapiens North America Customer Summit


ODG by MCG

ODG by MCG

“I am looking forward to sharing how ODG’s evidence-based solutions can help Sapiens’ customers effectively return people to health and productivity.” – Dave Kukielka, Account Executive, ODG by MCG

ODG by MCG, an MCG Health company and part of the Hearst Health network, announces one of its resident workers’ compensation experts, Dave Kukielka, will participate in a panel discussion at the Sapiens North America Customer Summit 2022 happening on November 7-9, 2022 in Washington, D.C. This event offers three days of educational sessions and immersive workshops that bring together workers’ compensation insurance professionals to network and share ideas with Sapiens’ product teams and users.

Mr. Kukielka will join the panel, “Coach’s Message! Workers’ Compensation Panel Discussion,” on Wednesday, November 9, 2022, from 2:30 to 3:15 p.m. (ET). This session will address issues important to the workers’ compensation industry including how to expedite claim decisions, improve the coordination of care for injured workers, and help improve return-to-work probability. Mr. Kukielka will share how ODG has partnered with Sapiens to provide risk scoring, return-to-work durations, cost calculations, and automation/adjudication of bill reviews.

“It is so important to partner with other leaders in the workers’ compensation insurance industry as we are all focused on creating solutions to improve the customer experience,” said Kukielka. “I am looking forward to sharing how ODG’s evidence-based solutions can help Sapiens’ customers effectively return people to health and productivity.”

Dave Kukielka has over 13 years of experience in the disability and workers’ compensation insurance industry. He has worked in many different roles, including editorial support for the development of evidence-based guidelines, business analyst, and account management.

For those interested in attending the Sapiens North America Customer Summit 2022, registration details and additional information can be found at: https://web.cvent.com/event/f8d68c04-0c11-487c-8458-583a8e67ec08/summary.

###

About ODG

ODG, an MCG Health company, (http://www.mcg.com/odg) provides unbiased, evidence-based guidelines that support payers, providers, employers, and auto insurers in their efforts to confidently and effectively return people to health. The clinical guidelines and analytical tools within ODG are designed to improve and benchmark return-to-work performance, facilitate quality care while limiting inappropriate utilization, assess claim risk for interventional triage, and set reserves based on industry data.

About MCG

MCG, part of the Hearst Health network, helps healthcare organizations implement informed care strategies that proactively and efficiently move people toward health. MCG’s transparent assessment of the latest research and scholarly articles, along with our own data analysis, gives patients, providers, and payers the vetted information they need to feel confident in every care decision, in every moment. For more information visit http://www.mcg.com or follow our Twitter handle at @MCG_Health.

Share article on social media or email:



Identity tech firm, IDScan.net, to debut cannabis vending machine at MJBizCon 2022


Image of Age Restricted Vending machine by IDScan.net

Image of Age Restricted Vending machine by IDScan.net

“Other companies that have attempted to launch cannabis vending machines have really overcomplicated it. They make you download an app, or they use vein reading technology. For us it all comes down to the scan of an ID,” said IDScan.net Director of Cannabis Business, Kenny Peddicord.

IDScan.net’s new marijuana vending machine will debut at November’s MJBizCon in Las Vegas, the world’s largest cannabis industry conference. With a 43” touchscreen, room for up to 450 individually packaged cannabis products, and a robotic interior manufactured by FastCorp Vending, Age Restricted Vending (ARV) is the first of its kind.

IDScan.net’s cannabis vending machine overcomes the primary hurdle which has stymied launches of other brands – age and identity verification. By integrating a best-in-class ID authentication device, the machine is able to detect nearly 98% of fake IDs. And by using a high resolution webcam and proprietary anti-spoofing software, the machine matches the purchaser to the image on the ID. Because of the system’s high degree of accuracy, no attendant is required to dispense age restricted products, and the entire process can be completed in less than 15 seconds.

Unattended retail is expected to grow to a $46B market by 2027, driven by consumer desire for convenience and touch-free purchase. However, cannabis has been unable to get in on the action due to strict laws around age verification, operational hours, and dispensary zoning. Cannabis vending machines have the potential to combat all of these challenges.

“Other companies that have attempted to launch cannabis vending machines have really overcomplicated it. They make you download an app, or they use vein reading technology. For us it all comes down to the scan of an ID,” said IDScan.net Director of Cannabis Business, Kenny Peddicord.

“We have been authenticating IDs for more than 20 years and we knew that using IDs and facial recognition would be the easiest, most secure, way to perform age verification.” The system uses tools and workflows similar to what is already being used in many of the country’s top dispensaries.

In addition to age verification powered by IDScan.net, the machine also boasts Thru Solutions’ best-in-class inventory management software and purchasing interface. Checkout and payment processing is performed using a MagTek DynaFlex Pro, which supports swipe, chip insert, and tap payments for cannabis products. MagTek’s Magensa Decrypt and Forward Gateway service is being used to provide point-to-point encryption for sensitive data.

ARV is rated for outdoor use, and does not require Wi-Fi, making it ideal for a variety of environments including festivals and events.

“In my years in the unattended retail business I have received thousands of inquiries from businesses looking to sell cannabis, alcohol, and other products which require age verification,” said Dave Russo, CEO of DSR35. “This is the first time we’ve been able to verify age at the machine. Our solution operates with far more accuracy than a bouncer checking an ID in a dark bar. You can be very confident in a customer’s identity even without a budtender present.” DSR35 has already shipped similar machines for the sale of other age restricted products such as CBD and ammo.

ARV will be on display in IDScan.net’s booth #2319 on-site at MJBizCon, November 16-18 in Las Vegas. Conference attendees will be able to test the machine by scanning their ID. Though the machine won’t be dispensing cannabis at the conference it will be dispensing fun swag from IDScan.net as well as other contributors to the machine’s technology.

About IDScan.net

IDScan.net is an AI-powered identity verification platform powering the ID validation and identity proofing strategies of more than 750 cannabis dispensaries and 6,500 global businesses. We focus on outstanding customer experience, data automation, and fraud reduction for high compliance industries.

Share article on social media or email:

John Tytko Joins Avaneer Health as Chief Financial Officer


John Tytko has been named Chief Financial Officer of Avaneer Health

“I am thrilled to join Avaneer Health, a company that is committed to fixing the fundamental challenges with long-standing data silos and a lack of data fluidity that the healthcare industry has been facing for years,” said John.

Avaneer Health, a secure digital network for healthcare, today announced that John Tytko has been named Chief Financial Officer (CFO). Tytko will lead financial management activities while supporting corporate development initiatives and guiding strategic growth initiatives. The addition of Tytko completes the appointment of the executive leadership team at Avaneer Health.

Tytko has a track record of driving operational efficiencies, maximizing profit, and tying employee engagement to enterprise value. Prior to joining Avaneer Health, Tytko was vice president of finance at Caremerge, Inc., a private company specializing in clinical and engagement SaaS solutions for senior living healthcare companies. While there, Tytko focused on financial reporting, risk management, regulatory compliance, employee culture, and corporate governance. He also assisted in leading Caremerge to a strategic exit in 2022. Most recently, Tytko served as chief financial offers at SupplyShift, a climate-tech platform for ESG initiatives.

“I am pleased to welcome John to our leadership team,” said Stuart Hanson, CEO of Avaneer Health. “His deep and extensive experience in leading the financial operations of healthcare organizations will make an immediate impact as we launch the Avaneer Network™ and scale for providers, payers, and innovators. I am confident that John will provide strong leadership and will be an excellent addition to the Avaneer Health team.”

“I am thrilled to join Avaneer Health, a company that is committed to fixing the fundamental challenges with long-standing data silos and a lack of data fluidity that the healthcare industry has been facing for years,” said John. “I look forward to working with the team to achieve interoperability and to improve the healthcare experience for providers, payers and patients.”

About Avaneer Health

Avaneer Health is a secure digital network designed for healthcare to collaborate and share data real-time, simplifying healthcare administration. Built on innovative technologies, the Avaneer NetworkTM will facilitate access to updated data for transparency and interoperability in healthcare through a decentralized network. Through a permissioned process, data can be shared with anyone on the network while remaining in the creator’s control. First of its kind, Avaneer Health allows for true collaboration between industry stakeholders and technology vendors to launch solutions that streamline and speed administrative processes, improving the healthcare experience. Avaneer Health was founded in 2020 by a consortium of industry leaders including Aetna, a CVS Health company; Elevance Health; Cleveland Clinic; Health Care Service Corporation, a Mutual Legal Reserve Company (HCSC); Merative; The PNC Financial Services Group, Inc.; and Sentara Healthcare. For more information, visit AvaneerHealth.com and follow Avaneer Health on LinkedIn and Twitter.

Share article on social media or email:



IO360º, Reporting on the Latest Progress for Cancer Immunotherapy Announces 2023 Keynotes, Plenary Sessions and a Full Day on IO Cell Therapy


“With the field of cell therapy rapidly advancing with exciting data, it became necessary to dedicate a full day to cell therapy for cancer immunotherapies,” – Kate Woda, Director, Immuno-Oncology 360º

The Conference Forum announced the launch of the 9th annual Immuno-Oncology 360º Summit (IO360°) taking place February 7-10, 2023 at the New York Marriott at the Brooklyn Bridge, in Brooklyn, NY.

“With the field of cell therapy rapidly advancing with exciting data, it became necessary to dedicate a full day to cell therapy for cancer immunotherapies,” said Kate Woda, Director of Immuno-Oncology 360º. “We are pleased to expand the program, to allow for more keynote speakers, more presentations and ultimately more data that is pushing the field forward.”

The IO360° 2023 keynotes and featured speakers include:

Marcela Maus, MD, PhD, a pioneer in the area of adoptive cell therapy and Director of Cellular Immunotherapy at Massachusetts General Hospital will address mechanisms of action driving CAR-T cells, why some programs don’t seem to work, and what can be done to solve for those issues.

Isabelle Rivière, PhD, cell therapy manufacturing expert and Director, Cell Therapy and Cell Engineering Laboratory, Memorial Sloan Kettering Cancer Center will deliver a keynote marking the progress on cell therapy manufacturing to include autologous, allogeneic, in vivo and point-of-care products.

The most prestigious analyst in IO, Andrew Baum, MD, Citi’s Head of Global Healthcare and Managing Director, Equity Research for Citi, will return to the IO360º stage for his annual keynote, for what is next on the IO radar, and what his top 10 recommendations are.

Arjun Goyal, MD, Co-founder and Managing Director, Vida Ventures, will provide his perspective as an expert investor on the overview of the current market, its future and the impact of the IO cell therapy field.

Patient keynote, Oswald Peterson, will bring an extraordinary perspective as a Stage IV lung cancer survivor and will share his story from diagnosis through to immunotherapy treatments that saved his life.

The main plenary sessions for 2023 cover:


  • Cell Therapy
  • Discovery / Preclinical
  • Biomarkers / Assay Development
  • Translational Science
  • RNA Therapeutics
  • Clinical Developments
  • Imaging Advancements
  • Clinical Operations
  • Business Developments

For the first time a full day will be dedicated to cellular cancer immunotherapy, called IO Cell Therapy 360º. This will be chaired by Teri Foy, MD, PhD, BMS, Aiman Shalabi, PharmD, GSK, Michael Kalos, PhD, Next Pillar Consulting and Ramy Ibrahim, MD, bit.bio.

To learn more about the event, visit io360summit.com.

About Immuno-Oncology 360º:

IO360˚ is an annual conference in NYC that convenes key stakeholders spanning the science and business communities to report on the latest data impacting immuno-oncology to fight a wider range of cancers.

About the Conference Forum:

The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused. The company also publishes six newsletters and produces PharmaTalkRadio and virtual events.

Share article on social media or email: